このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

IDeAS Probiotic Pilot (IDeAS)

2026年11月9日 更新者:Stephanie A. Fritz、Washington University School of Medicine

Investigating Staphylococcus Aureus Colonization Dynamics in the Context of Bacillus Probiotic

Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.

Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.

In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.

研究の種類

観察的

入学 (推定)

20

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Stephanie Fritz, MD, MSCI
  • 電話番号:(314) 454-4114
  • メール:Fritz.s@wustl.edu

研究連絡先のバックアップ

  • 名前:Mary Boyle, RN, MSN
  • 電話番号:3(14) 286-1207
  • メール:mboyle@wustl.edu

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.

説明

Inclusion Criteria

  1. Colonized with S. aureus in anterior nares, inguinal folds, or stool
  2. Age ≥ 18 years
  3. Able to complete the informed consent process
  4. Willing and able to complete the study protocol, study-related activities, and visits

Exclusion Criteria

  1. Pregnant or planning to become pregnant in the next 9 months
  2. Breastfeeding
  3. Abnormalities of the gastrointestinal tract (e.g., inflammatory bowel disease, ulcers, celiac diseases, etc.)
  4. Immunodeficiency
  5. Use of any antibiotics or probiotics outside of the study within 90 days of study screening
  6. Any contraindication to taking probiotics
  7. No permanent home, or living in a group home/ long term care facility

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)
時間枠:Start of the pre-intervention phase and end of the intervention phase

Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling.

Start of the pre-intervention phase and end of the intervention phase
Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.
時間枠:End of the intervention phase and end of the post-intervention phase

Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification.

End of the intervention phase and end of the post-intervention phase

二次結果の測定

結果測定
メジャーの説明
時間枠
S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.
時間枠:Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus nares pre-intervention to week-6 sampling.
時間枠:Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus nares pre-intervention to month 2 sampling.
時間枠:Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus nares pre-intervention to month 3 sampling.
時間枠:Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus nares pre-intervention to month 4 sampling.
時間枠:Pre-intervention to month 4 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling.

Pre-intervention to month 4 sampling.
S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.
時間枠:Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus inguinal fold pre-intervention to week-6 sampling.
時間枠:Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus inguinal fold pre-intervention to month 2 sampling.
時間枠:Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus inguinal fold pre-intervention to month 3 sampling.
時間枠:Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus inguinal fold pre-intervention to month 4 sampling.
時間枠:Pre-intervention sampling to month 4 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling.

Pre-intervention sampling to month 4 sampling.
Bacillus stool pre-intervention
時間枠:Pre-intervention sampling

log10 B. subtilis CFU count at pre-intervention sampling

Pre-intervention sampling
Bacillus stool week-2 sampling
時間枠:Week-2 sampling

log10 B. subtilis CFU count at week-2 sampling

Week-2 sampling
Bacillus stool week-4 sampling
時間枠:Week-4 sampling

log10 B. subtilis CFU count at week-4 sampling

Week-4 sampling
Bacillus stool week-6 sampling
時間枠:Week-6 sampling

log10 B. subtilis CFU count at week-6 sampling

Week-6 sampling
Bacillus stool month 2 sampling
時間枠:Month 2 sampling

log10 B. subtilis CFU count at month 2 sampling

Month 2 sampling
Bacillus stool month 3 sampling
時間枠:Month 3 sampling

log10 B. subtilis CFU count at month 3 sampling

Month 3 sampling
Bacillus stool month 4 sampling
時間枠:Month 4 sampling

log10 B. subtilis CFU count at month 4 sampling

Month 4 sampling

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Stephanie A Fritz, MD, MSCI、Washington University School of Medicine

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2030年11月1日

研究の完了 (推定)

2031年11月1日

試験登録日

最初に提出

2026年11月9日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 202609172

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。